Numerous clinical trials have been registered to evaluate the efficacy of FGF21 analogues in the treatment of obesity, T2DM, hypertriglyceridemia, and MASH [311,312]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.